Hepatitis C Virus Therapy for Decompensated and Posttransplant Patients

Journal of Clinical Gastroenterology

Volumn 51, Issue 3, 2017, Pages 215-222

  Dailey, Francis ^a   Ayoub, Walid S ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

daclatasvir; decompensated cirrhosis; decompensated liver disease; hepatitis C; ledipasvir; liver transplant; paritaprevir; postliver transplant; sofosbuvir; velpatasvir

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIVER TRANSPLANTATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; LIVER CIRRHOSIS; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POSTOPERATIVE PERIOD; PRACTICE GUIDELINES AS TOPIC;

EID: 85011850209     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000701     Document Type: Review

References (31)

1. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. site]. 2016. Available at: http://www.hcvguidelines.org/full-report/unique-patient-populationspatients-decompensated-cirrhosis. Accessed January 23, 2016.
2. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016;63:1493-1505.
3. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-659.
4. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685-697.
5. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384: 1756-1765.
6. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618-2628.
7. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-1493.
8. Lawitz E, Poordad F, Gutierrez J, Kakuda T, et al. Simeprevir plus daclatasvir and sofosbuvir in treatment-naïve and treatment-experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: interim results from the Phase II IMPACT study In: 50th annual Meeting of the European Association for the Study of the Liver. Vienna, Austria; 2015.
9. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015;61:769-775.
10. Terrault N, Sulkowski M, Di Bisceglie A, et al. Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study. In: 2015 Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, California; 2015.
11. Osinusi A, Kohli A, Marti MM, et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an openlabel pilot study. Ann Intern Med. 2014;161:634-638.
12. Yee BE, Nguyen NH, Jin M, et al. Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials. BMJ Open Gastroenterol. 2016;3:e000056.
13. Flamm SLEG, Charlton M, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. In: 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, Massachusetts; 2014.
14. Gane EJHR, An D, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. In: 49th Annual Meeting of the European Association for the Study of the Liver. London, England; 2014.
15. Hezode CDLV, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. In: 2015 Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, California; 2015.
16. Welzel TMPJ, Ferenci R, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program. In: 2015 Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, California; 2015.
17. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714-725.
18. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312:353-361.
19. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. 2016. Available at: http://www.hcvguide lines.org/full-report/unique-patient-populations-patients-whodevelop-recurrent-hcv-infection-post%E2%80%93liver. Acces sed January 23, 2016.
20. EASL. EASL clinical practice guidelines. 2016. Available at: http://www.easl.eu/research/our-contributions/clinical-practiceguidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015/report/4. Accessed January 23, 2016.
21. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211-221.
22. AASLD-IDSA. Recommendations for Testing, Managing, and Treating Hepatitis C. site]. Available at http://www.hcvguide lines.org/full-report/unique-patient-populations-patients-whodevelop-recurrent-hcv-infection-post%E2%80%93liver. Acces sed January 23, 2016.
23. Kohler JJ, Nettles JH, Amblard F, et al. Approaches to hepatitis C treatment and cure using NS5A inhibitors. Infect Drug Resist. 2014;7:41-56.
24. Fontana RJ, Brown R, Herzer J, et al. Daclatasvir (DCV) combined with sofosbuvir (SOF) or simeprevir (SMV) in liver transplant (LT) recipients with severe recurrent HCV genotype 1 infection. In: 50th Annual Meeting of the European Association for the Study of the Liver (EASL), 2015, Vienna, Austria.
25. Herzer K, Papadopoulos-Kohn A, Walker A, et al. Daclatasvir, simeprevir and ribavirin as a promising interferon-free triple regimen for HCV recurrence after liver transplant. Digestion. 2015;91:326-333.
26. Dieterich D, Bacon B, Flamm S, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network [AASLD abstract 46]. Hepatology. 2014:60.
27. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2015;150:419-429.
28. Nguyen NH, Yee BE, Chang C, et al. Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis. BMJ Open Gastroenterol. 2016;3:e000066.
29. Mantry PS, Kwo PY, Coakley E, et al. High sustained virologic response rates in liver transplant recipients with recurrent HCV genotype 1 infection geceiving ABT-450/r/ombitasvir+dasabuvir plus ribavirin. In: 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, Massachusetts; 2014.
30. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375-2382.
31. Wong KA, Worth A, Martin R, et al. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother. 2013;57:6333-6340.